Pfizer-Pharmacia: the smart fit for the future

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.1, 2003-01, pp. : 1-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pfizer-Pharmacia: the postmerger

By Wiggins Phillip

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1761-1763

Informa Healthcare

Access to resources Recommend Favorite

Since Novartis' COX-2 inhibitor lumiracoxib [`Prexige'] has failed to demonstrate features differentiating it from the class leader celecoxib [`Celebrex; Pfizer/Pharmacia'], it could have limited market success

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 403, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Pharmacia Corp.: analysis of patenting 1998 – 2002

By Adams Stephen

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 2, 2002-02 ,pp. : 223-231

Informa Healthcare

Access to resources Recommend Favorite

Pfizer pulls the plug on Mylotarg

Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Pfizer: analysis of patenting 1995 - 1998

By Adams S.

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 11, 1998-11 ,pp. : 1405-1414

Informa Healthcare

Access to resources Recommend Favorite